NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. The company provides oncology diagnostic solutions that enable precision medicine. Management will host a webcast and conference call at 4:30 p.m. ET to discuss the financial results and recent highlights.

Conference Call Details

The live webcast can be accessed through the Investor Relations section of the company website at ir.neogenomics.com. An archived replay will be available shortly after the call concludes.

To participate via telephone, investors must dial at least five minutes prior to the start time. The domestic number is (888) 506-0062, while the international number is (973) 528-0011. The participant access code required to join the call is 968605.

About NeoGenomics

NeoGenomics is a cancer diagnostics company specializing in cancer genetics testing and information services. It offers a comprehensive oncology-focused testing menu across the cancer continuum. The company serves oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to guide personalized care decisions.

Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories throughout the US. It also maintains a CAP-accredited full-service sample-processing laboratory in Cambridge, England.

NeoGenomics, Inc. has appointed Carolyn Starrett to its Board of Directors to strengthen its expertise in data and technology within the cancer diagnostics sector. The appointment leverages Starrett's extensive background in artificial intelligence and data insights to enhance the company's strategic direction. This move aims to bolster NeoGenomics' portfolio and impact for cancer patients through advanced diagnostic solutions.

Starrett brings over 25 years of experience in commercial, product, and operations roles at data and technology companies. From 2016 to 2026, she served at Flatiron Health, holding various executive positions, including CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting firm focused on healthcare delivery, drug development, data, and AI.

Board Expertise and Strategic Fit

Lynn Tetrault, Chair of the Board of NeoGenomics, expressed enthusiasm about the appointment, highlighting Starrett's experience with real-world data and analytics. Tetrault noted that Starrett's insights will be valuable as the company continues to expand its offerings. Starrett previously served as a Board Director at Foundation Medicine from 2021 to 2024 and held leadership roles at a predictive analytics company and Boston Consulting Group.

Educational Background

Starrett holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor's degree from Brown University. Her academic and professional background aligns with NeoGenomics' focus on precision medicine and oncology diagnostics.

About NeoGenomics

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. It offers a comprehensive oncology-focused testing menu, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms. Headquartered in Fort Myers, FL, the company operates CAP-accredited and CLIA-certified laboratories across the US and in Cambridge, England.